Objective
To achieve (i) effective protective immunity, (ii) a high population response, (iii) prolonged duration of immunity, and (iv) high level of safety, novel vaccines should combine the efficacy of live (attenuated) vaccines and the safety of subunit vaccines. A vaccine resulting in antigen presentation which mimics that during natural infection by the cognate pathogen would appear have the highest probability of success.
The present proposal presents a novel strategy of vaccine design to meet the above goals. Vaccine vectors are described which are based on a self-replicating, suicidal, recombinant RNA, originating from Semliki Forest virus (SFV). In this system, genes encoding relevant antigens are cloned into vectors which upon vaccination will transiently express the antigen within the cells of the host. Preliminary studies have already shown that this strategy results in a strong induction of the humoral and cellular arms of the immune system with sustained immunologic memory. Extensive in-depth studies are described to further characterize the immune responses for optimal design of individual vaccines. These studies will, among others, include the co-expression of antigen and cytokines and/or co-stimulatory factors. The present proposal further describes development of the SFV system to allow efficient delivery of vaccines as infectious, suicidal virus particles, as naked nucleic acids (NA) or as NA-lipid complexes. A number of vaccine candidates will be employed to test the functionality and efficacy of the SFV system as a transdisease vaccine strategy. Diverse applications will cover vaccines directed against influenza virus, flavivirus, lentivirus and papilloma virus infection as well as cancer.
The SFV system is by design quite safe, but studies will be conducted to further address biosafety, in preparation for human trials. Work is also described for the design of scale up production of vaccine preparations. Finally, industrial links are already in place for rapid exploitation of results stemming from this Project.
The tasks outlined in this Project proposal will comply with most, if not all, objectives set forth in the EC Biotechnology Workprogramme.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases RNA viruses influenza
- medical and health sciences basic medicine immunology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
171 77 Stockholm
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.